SUPRPEP is developed by Eisenhower Army Medical Center.

What development phase is SUPRPEP in?

SUPRPEP is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

SUPRPEP

Eisenhower Army Medical Center · FDA-approved active Small molecule Quality 4/100

Suprpep, marketed by Eisenhower Army Medical Center, is a small molecule with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with specific biological molecules to produce a therapeutic effect, though its primary indication and revenue figures are not specified. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	SUPRPEP
Sponsor	Eisenhower Army Medical Center
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Colonoscopy Bowel Prep Comparison Among Diabetic Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SUPRPEP CI brief — competitive landscape report
SUPRPEP updates RSS · CI watch RSS
Eisenhower Army Medical Center portfolio CI